losartan has been researched along with Neoplasms in 11 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome." | 4.80 | Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000) |
| "Incident cancer cases were compared in patients randomized to ARBs versus controls." | 2.47 | Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ( , 2011) |
| "Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26." | 2.47 | Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. ( Chang, CH; Lai, MS; Lin, JW; Wu, LC, 2011) |
| "Although some tumors had vessels with greater oxygen-carrying ability than those of normal skin, most tumors had inefficient vessels." | 1.72 | Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition. ( Bawendi, MG; Brown, EB; Chauhan, VP; Duda, DG; Fukumura, D; Han, HS; Jain, RK; Kamoun, WS; Lanning, RM; Lee, H; Martin, JD; Martin, MR; Mousa, AS; Padera, TP; Stylianopoulos, T, 2022) |
| "Telmisartan-treated tumours were more responsive to radiation, indicating that telmisartan reduces a therapeutically important population of transiently hypoxic tumour cells." | 1.56 | Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. ( Benard, F; Bennewith, KL; Cederberg, RA; Colpo, N; Firmino, NS; Franks, SE; Lee, CM; Lin, KS; Pan, J; Wadsworth, BJ, 2020) |
| "However, cancer gene therapy has been challenged by the inherent limitation of vectors that are able to deliver therapeutic genes to tumors specifically and efficiently following systemic administration." | 1.42 | Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors. ( Asavarut, P; Hajitou, A; Lee, EL; Suwan, K; Syed, N; Yata, T, 2015) |
| "Treatment with losartan alone did not suppress tumor growth; In contrast, treatment with doxorubicin alone decreased tumor growth; losartan and doxorubicin were administered in combination, had a synergistic effect that the tumor growth was much more inhibited." | 1.42 | Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor. ( Hu, SQ; Li, XY; Liu, JX; Wang, LY; Xiao, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Tukey, RH | 1 |
| Strassburg, CP | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Martin, JD | 1 |
| Lanning, RM | 1 |
| Chauhan, VP | 1 |
| Martin, MR | 1 |
| Mousa, AS | 1 |
| Kamoun, WS | 1 |
| Han, HS | 1 |
| Lee, H | 1 |
| Stylianopoulos, T | 1 |
| Bawendi, MG | 1 |
| Duda, DG | 1 |
| Brown, EB | 1 |
| Padera, TP | 1 |
| Fukumura, D | 1 |
| Jain, RK | 1 |
| Guo, F | 1 |
| Jiao, Y | 1 |
| Du, Y | 1 |
| Luo, S | 1 |
| Hong, W | 1 |
| Fu, Q | 1 |
| Li, A | 1 |
| Wang, G | 1 |
| Yang, G | 1 |
| Wadsworth, BJ | 1 |
| Cederberg, RA | 1 |
| Lee, CM | 1 |
| Firmino, NS | 1 |
| Franks, SE | 1 |
| Pan, J | 1 |
| Colpo, N | 1 |
| Lin, KS | 1 |
| Benard, F | 1 |
| Bennewith, KL | 1 |
| Shen, H | 1 |
| Gao, Q | 1 |
| Ye, Q | 1 |
| Yang, S | 1 |
| Wu, Y | 1 |
| Huang, Q | 1 |
| Wang, X | 1 |
| Sun, Z | 1 |
| Yata, T | 1 |
| Lee, EL | 1 |
| Suwan, K | 1 |
| Syed, N | 1 |
| Asavarut, P | 1 |
| Hajitou, A | 1 |
| Scherrer-Crosbie, M | 1 |
| Xiao, L | 1 |
| Hu, SQ | 1 |
| Wang, LY | 1 |
| Liu, JX | 1 |
| Li, XY | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
4 reviews available for losartan and Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Contro | 2011 |
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
7 other studies available for losartan and Neoplasms
| Article | Year |
|---|---|
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition.
Topics: Angiotensins; Animals; Hypoxia; Losartan; Mice; Microscopy; Neoplasms; Oxygen; Receptors, Angiotensi | 2022 |
Enzyme-responsive nano-drug delivery system for combined antitumor therapy.
Topics: Animals; Cell Line, Tumor; Collagen; Curcumin; Drug Delivery Systems; Losartan; Matrix Metalloprotei | 2022 |
Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; C | 2020 |
Peritumoral implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Endocytosis; Fluo | 2018 |
Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors.
Topics: Animals; Bacteriophages; Cell Death; Cell Line, Tumor; Cell Survival; Collagenases; Dependovirus; Di | 2015 |
Losartan: A new treatment for cardiac cachexia?
Topics: Angiotensin II; Blood Pressure; Cachexia; Humans; Losartan; Myocardium; Neoplasms | 2015 |
Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents | 2015 |